Mazyar Shadman, MD, on Growing Research Trends in LBCL
The associate professor at Fred Hutch Cancer Center discussed trends he observed in the field in 2023 and at ASH 2023.
Mazyar Shadman, MD, on Investigating Treatment Choices With CAR-T and Auto-HSCT in LBCL
The associate professor at Fred Hutch Cancer Center discussed data from a retrospective analysis of patients treated with tisa-cel, axi-cel, or liso-cel.
Mazyar Shadman, MD, on Evaluating MB-106 in a Multicenter Study
The associate professor at Fred Hutch Cancer Center discussed new data on the CD20-targeting CAR he presented at ASH 2023.
Mazyar Shadman, MD, MPH, on Addressing Unmet Needs in Follicular Lymphoma With MB-106
The associate professor at Fred Hutch Cancer Center discussed next steps with the clinical trial being conducted Fred Hutch Cancer Center.
Mazyar Shadman, MD, MPH, on MB-106's Potential in Follicular Lymphoma
The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.
Evaluating MB-106 in B-NH Lymphoma and CL Leukemia: Mazyar Shadman, MD
The associate professor from Fred Hutchinson Cancer Research Center discussed the methods utilized in an ongoing phase 1/2 trial evaluating MB-106.
Dr. Shadman on Next Steps for CAR T-Cell Therapy in DLBCL
Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses next steps for CAR T-cell therapy in diffuse large B-cell lymphoma.